DS-1594
Phase 2
Daiichi SankyoDS-1594 is one of 33 therapeutic programs targeting Pancreatic Carcinoma. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
48 competitors in Pancreatic Carcinoma
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaApproved
Gemzar
Johnson & JohnsonPhase 3
Camptosar
PfizerPhase 3
Eloxatin
TevaPhase 3
Imfinzi
AstraZenecaPhase 3
Folinic Acid
RochePhase 3
BMS-986205
Bristol-Myers SquibbPhase 3
Iressa
AstraZenecaPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Tuoyi
SSun Yat-sen University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for DS-1594. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company